Tag Archives: AAV

November, 2018

September, 2017

January, 2016

  • 6 January

    ChemoCentryx Rare Disease Drug as Effective as Standard of Care in Mid-Stage Study

    MOUNTAIN VIEW, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced positive top-line data from its’ Phase II CLEAR trial with CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, or …